MAPK1 and neoplasm: In addition, Ras/ERK pathway hyperactivation is a common feature of a variety of tumor types with activating mutations in KRAS, NRAS, or BRAF [10]; however, mutations in these genes were detected in only ~3.2% of all breast lesions [11].